There has been one stock split for Dexcom stock (symbol: DXCM) that took place on June 13th, 2022.

Dexcom has positively influenced the life of diabetic patients with time. The company is the pioneer manufacturer of real-time diabetes-checking devices and has gained popularity with time. Its robust business is visible in continuously growing business which has risen roughly by 38%. However, the rise in stock prices in the recent five years has been incredible, as they have climbed by 482%. Over the past years, the share gained mid-blogging by 4,550%.

Dexcom Stock Split History

[table id=166 /]

Recently, the company announced the news of its stock splitting. The company has planned to split its shares in a 4-for-1 ratio. It implies that a shareholder who owns a single share will now possess an extra three shares.

This stock split will increase the number of available stocks which are feasible for small investors and other commoners. The split not only provides more vacant portals for the investors but also makes it affordable as stock prices are cut down in a stock split.

This stock split will increase the number of available shares from 200,000,000 to 800,000,000. At the time of the announcement, the company was trading at $480 a share in the stock market. With a 4-for-1 stock split, the share prices will reduce to $120 per share.

The board of directors discussed the split in their meeting held in May, and the company started trading based on the new splits on 10 Jun 2022.

Dexcom Performance in Latest Quarter

According to reports, the revenue generated in the second quarter of 2022 was $696.2 million, which is 17% higher than the amount earned last year during the same quarter. The gross profit of 2022 was as high as $449.5m, or 64.6% of revenue. At the same time, it was $417.1m, 70.1%, of revenue in the second quarter of 2021. The immense growth is visible through these figures. Likewise, the company’s GAAP net income was recorded to be $50.9m, or $0.12 per diluted share, in the second quarter of 2022. Comparing this year’s GAAP net income with the numbers in the second quarter of last year, the GAAP net income was $78.4m, or $0.19 per diluted share. The figures show that the company is on a journey to big success as its economy is progressive and is growing with time.

Looking forward to the future performance of the company, the company has issued a guidebook that predicts revenue growth from $2.86 billion to $2.91 billion. This represents growth between 17% to 19%.

FAQs

Why is DexCom StockDropping?

The decline in stock was recorded after the company put forth its report for the second quarter. The stock prices of the diabetes care technology company dropped.

Is DexCom Stock ood Buy?

According to 14 wall street analysis, the Dexcom stock is a good buy for most investors as the firm has announced its split, and the growth of the company is progressive as well.

How many times has Dexcom split?

In the history of the Dexcom database, the company has witnessed only a single split incidence since the company was founded.